Testing DNP002 for advanced solid tumors that have not responded to standard treatments
Part of Cancer clinical trials.
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older and have a solid tumor that cannot be removed by surgery or has spread to other parts of your body.
- Your cancer has not responded to or has progressed after standard treatment, and there are no other standard treatment options available.
- You have at least one tumor that can be measured on a scan.
- Your expected survival is at least 12 weeks, and you are able to take care of yourself (ECOG performance status 0–1).
- Your major organs (like bone marrow, liver, kidneys) are working well, and you have recovered from side effects of prior cancer treatments.
- You are not pregnant (if applicable), and you agree to use effective contraception during the study and for 24 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This trial tests a new drug called FP002 for people with advanced solid tumors that have not responded to or cannot have standard treatments. It aims to see if the drug is safe and can help shrink or control the cancer.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.